Contract facts
UnrestrictedDEVELOPING IN-007 AS A WIDELY DEPLOYABLE INHALED TREATMENT AGAINST PATHOGENS UTILIZING HUMAN ACE2 FOR VIRAL ATTACHMENT AND ENTRY is a federal Unrestricted award for Army Med Res Acq Activity held by Inhalon Biopharma, Inc. Estimated value $2.2M ($2.2M obligated). Current period of performance ends Dec 22, 2026. Last award drew 47 bidders. Place of performance: MORRISVILLE NC. Related solicitation HT942523SJWMR.
DEVELOPING IN-007 AS A WIDELY DEPLOYABLE INHALED TREATMENT AGAINST PATHOGENS UTILIZING HUMAN ACE2 FOR VIRAL ATTACHMENT AND ENTRY
Recompete timing
PublicCurrent PoP ends Dec 22, 2026 (86 days remaining). Agencies typically plan 12–18 months ahead — at 2.8 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on HT942524C0076? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordInhalon Biopharma, Inc — $5.4M obligated across 2 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT942524C0076?
HT942524C0076 (Developing in-007 as a WIDELY deployable) is a Army Med Res Acq Activity award with a potential value of $2.2M, currently held by Inhalon Biopharma, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HT9425-24-C-0076?
HT9425-24-C-0076 is the dashed form of PIID HT942524C0076 (Developing in-007 as a WIDELY deployable), held by Inhalon Biopharma, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HT942524C0076?
Army Med Res Acq Activity awarded HT942524C0076 to Inhalon Biopharma, Inc (potential $2.2M).
Who is the incumbent on HT942524C0076?
Inhalon Biopharma, Inc is the incumbent with $5.4M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Dec 22, 2026.
When does Inhalon Biopharma, Inc’s HT942524C0076 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 22, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on HT942524C0076? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.